Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.56 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 0.56 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.48 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8964576 | 0.99 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1L3MBTL4MBTD1HSD17B14 | |
| SCHEMBL15930667 | 0.91 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1L3MBTL4MBTD1HSD17B14 | |
| SCHEMBL8964313 | 0.88 | HSD17B14 (0.49) | L3MBTL3L3MBTL1L3MBTL4MBTD1HSD17B14 | |
| SCHEMBL9011525 | 0.81 | PRKCQ (0.53) | MBTD1OPRK1HSD11B1HRH3 | |
| SCHEMBL9011442 | 0.80 | PRKCQ (0.54) | OPRK1HRH3 | |
| SCHEMBL8963966 | 0.79 | HSD17B14 (0.55) | HSD17B14HSD11B1HTTMEN1NPC1 | |
| SCHEMBL8964454 | 0.79 | HSD17B14 (0.42) | HSD17B14HSD11B1HTTMEN1NPC1 | |
| SCHEMBL8964520 | 0.78 | HTT (0.49) | L3MBTL3L3MBTL1HSD17B14HSD11B1HRH3 | |
| SCHEMBL8964821 | 0.77 | ALOX15 (0.44) | HSD17B14HTTALOX15 | |
| SCHEMBL8964283 | 0.77 | HSD17B14 (0.45) | L3MBTL3L3MBTL1HSD17B14HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | L3MBTL3 2612/4885L3MBTL1 2582/4885L3MBTL4 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.